Fortrea (FTRE) Q2 Revenue Jumps 7%

Fortrea Holdings (NASDAQ:FTRE), a contract research organization specializing in clinical trial services for pharmaceutical and biotechnology clients, reported its financial results for the second quarter of fiscal 2025 on August 6, 2025. The company delivered a notable revenue beat, posting $710.3 million (GAAP) for Q2 2025 against consensus analyst expectations of $631.46 million. Adjusted earnings per share (non-GAAP) reached $0.19, substantially ahead of the $0.08 estimate. The results marked growth in revenue and an improvement in adjusted net income compared to Q2 2024. However, A large non-cash goodwill impairment of $309.1 million in Q2 2025 led to a widened GAAP net loss, and The book-to-bill metric—an indicator of future growth—dropped below management’s target of 1.2x, with a reported ratio of 0.79x. Overall, the period showed operational improvement, but structural and market challenges persist. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Fortrea Holdings provides outsourced clinical development services for pharmaceutical and biotechnology industries. Its business spans all stages of clinical trials, also known as phases I through IV, which are required for drug and medical device approvals. In this role, Fortrea designs, manages, and analyzes data from global studies, supporting pharmaceutical companies as they develop new treatments.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool